Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of “Hold” by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been assigned an average recommendation of “Hold” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $5.25.

A number of equities analysts have recently commented on MRVI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th.

Insiders Place Their Bets

In related news, CEO Bernd Brust bought 216,212 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average cost of $3.25 per share, for a total transaction of $702,689.00. Following the purchase, the chief executive officer directly owned 466,771 shares in the company, valued at $1,517,005.75. This trade represents a 86.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory T. Lucier purchased 51,472 shares of Maravai LifeSciences stock in a transaction on Friday, December 5th. The stock was bought at an average cost of $3.70 per share, with a total value of $190,446.40. Following the completion of the acquisition, the director owned 106,595 shares in the company, valued at approximately $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 566,771 shares of company stock worth $1,880,244 in the last ninety days. 2.11% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its position in Maravai LifeSciences by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after buying an additional 5,160 shares in the last quarter. Performa Ltd US LLC increased its position in Maravai LifeSciences by 33.3% in the 2nd quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock valued at $55,000 after acquiring an additional 5,740 shares in the last quarter. Epacria Capital Partners LLC raised its stake in shares of Maravai LifeSciences by 6.8% in the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock worth $287,000 after acquiring an additional 6,384 shares during the last quarter. Ethic Inc. lifted its position in shares of Maravai LifeSciences by 62.8% during the third quarter. Ethic Inc. now owns 16,951 shares of the company’s stock worth $49,000 after purchasing an additional 6,540 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Maravai LifeSciences by 121.1% during the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after purchasing an additional 9,870 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Trading Down 3.1%

Shares of MRVI stock opened at $3.71 on Wednesday. The business’s 50 day moving average is $3.61 and its two-hundred day moving average is $3.08. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $6.05. The company has a market cap of $948.68 million, a PE ratio of -4.42 and a beta of 0.33.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The firm had revenue of $41.63 million for the quarter, compared to the consensus estimate of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. Equities analysts predict that Maravai LifeSciences will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.